Article: FDA Approves Elan's Migraine Drug Frova(TM) (frovatriptan succinate).

Article: Elan and UCB Announce Agreement to Co-Promote New Migraine Drug ...
PR Newswire;  March 28, 2002 ;     700+ words ... ... efficacy and tolerability of FROVA was demonstrated in five ... Center, Mt. Vernon, New York, "My experience with ... our partner in bringing FROVA to the U.S. market ... following administration of FROVA 2.5 mg tablets were ... Elan shares trade on the New York, London and Dublin ...

Article: Elan Announces Agreement with Vernalis Regarding North American ...
Business Wire;  March 30, 2004 ;     700+ words ... ... respectively. The carrying value of the Frova intangible asset is approximately ... the second quarter of 2004. About Frova Frova is a prescription medicine used for ... NYSE: ELN) shares trade on the New York, London and Dublin Stock Exchanges ...

Article: Drug makers tackle painful problems.(Frova (frovatriptan ...
Chain Drug Review;  August 14, 2006 ;     700+ words ...NEW YORK -- Efforts to develop products ... supplemental new drug application for Frova (frovatriptan succinate) 2 ... Food and Drug Administration, Frova will be the only triptan indicated ... prevention of MM. Currently, Frova is FDA-approved for the acute ...

Article: Elan Completes Sale of Frova to Vernalis.
Business Wire;  May 18, 2004 ;     577 words ... ... Elan and Vernalis regarding Frova(TM) (frovatriptan). Vernalis ... assets in North America for Frova. Under the terms of the agreement ... will receive a payment for its Frova inventory, estimated at approximately ... ELN) shares trade on the New York, London and Dublin Stock Exchanges ...

Article: Frova(R) Meets Primary Endpoint in Second Phase III Study ...
PR Newswire;  May 8, 2006 ;     700+ words ... ... the second Phase III efficacy study of Frova(R) (frovatriptan succinate) 2.5 ... approval for the additional indication of Frova(R) for the prevention of menstrual migraine. If approved, Frova(R) will be the only triptan indicated ...

Article: Vernalis plc Announces FDA Acceptance for Filing of ...
PR Newswire;  September 20, 2006 ;     700+ words ... ... supplemental New Drug Application (sNDA) for Frova(R) (frovatriptan succinate) 2.5 ... needed to assess the safety and efficacy of Frova(R) for the short-term prevention of ... Gregory Gin Notes to Editors The sNDA for Frova(R) is supported by data from four studies ...

Article: Endo Licenses Rights from Vernalis to Market Acute Migraine ...
PR Newswire;  July 14, 2004 ;     700+ words ... ... exclusive rights to market Vernalis's Frova(TM) (frovatriptan) in North America. Launched in the U.S. in June 2002, Frova(TM) is indicated for the acute treatment ... migraine headaches in adults. Net sales of Frova(TM) in the U.S. were $37.5 million ...